Document is current

Article History

Received: 13 March 2022

Accepted: 11 July 2022

First Online: 23 July 2022

Declarations

:

: Ethics approval for the following research was granted by the Conjoint Health Research Ethics Board at the University of Calgary (REB17–1563) and the Dutch IRB approval (UMCU METC no. 18–474).Informed consent was obtained from all individual participants and/or parents included in the study.

: Not applicable.

: DAM reports non-financial support from consultancy (Illumina) and ISPOR, and personal fees from Analytica, outside the submitted work. RSMY reports consulting fees from Novartis and Lily outside the submitted work. SV reports grants and personal fees from SOBI and Novartis during the conduct of the study. JS reports grants from SOBI and consultancy fee for Amgen, outside the submitted work. NW reports consulting fees from Novartis, Sanofi and Sobi outside the submitted work. All other authors declare that they have no competing interests. The authors have no other relevant affiliations or financial involvement with any organization or entity with a financial interest in or financial conflict with the subject matter or materials discussed in the manuscript apart from those disclosed.